Shigella dysenteriae type 1 lipopolysaccharide (Sd1 LPS)

Shigella dysenteriae type 1 lipopolysaccharide (Sd1 LPS) is a fundamental component of the outer membrane of the S. dysenteriae type 1 bacterium, the causative agent of epidemic bacillary dysentery. The molecule is composed of three distinct regions: the membrane-anchored Lipid A (endotoxin), a core oligosaccharide, and the O-antigen (O-specific polysaccharide), which is the primary determinant of serotype specificity and a major target for the host immune system (Morona et al., 2003, Journal of Bacteriology). In Sd1, the O-antigen repeat unit is uniquely structured, consisting of [→3)-α-L-Rhap-(1→3)-α-L-Rhap-(1→2)-α-D-Galp-(1→3)-α-D-GlcpNAc-(1→] (Pozsgay et al., 1999, PNAS). Sd1 LPS plays a dual role in pathogenesis: it provides a physical barrier against host defenses like bile salts and complement, and its Lipid A moiety acts as a potent agonist for Toll-like receptor 4 (TLR4), driving the severe localized and systemic inflammation characteristic of shigellosis (Poltorak et al., 1998, Science). From a therapeutic perspective, the O-antigen of Sd1 LPS is a high-priority target for the development of glycoconjugate vaccines and therapeutic monoclonal antibodies aimed at providing serotype-specific protection (Cohen et al., 1997, The Lancet). Current pharmaceutical research focuses on synthetic carbohydrate chemistry to create well-defined LPS-based antigens that overcome the limitations of traditional whole-cell or purified polysaccharide vaccines.

Other names

Shigella dysenteriae serotype 1 lipopolysaccharideSd1 O-antigenSd1 endotoxinShigella dysenteriae type 1 O-specific polysaccharideO-SP

Induction of protective O-antigen-specific IgG and IgA antibodies that facilitate opsonophagocytosis and bacterial neutralization (vaccines); binding to the Lipid A moiety to disrupt the bacterial outer membrane integrity (polymyxins).